Siga Technologies (SIGA) Other Non-Current Liabilities (2011 - 2025)
Siga Technologies' (SIGA) quarterly Other Non-Current Liabilities came in at $2.7 million in Q4 2025, down 17.1% on a YoY basis from $3.2 million in Q4 2024, and down 19.15% quarter-over-quarter from $3.3 million in Q3 2025.
Analysis
Siga Technologies (SIGA) Other Non-Current Liabilities (2011 - 2025) Analysis & Trends
Siga Technologies (SIGA) has reported Other Non-Current Liabilities for 15 consecutive years, with $2.7 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Liabilities fell 17.1% year-over-year to $2.7 million; the trailing twelve-month figure through Dec 2025 stood at $2.7 million (down 17.1% YoY), and the FY2025 full-year result was $2.7 million, down 17.1% from the prior year.
- Other Non-Current Liabilities declined to $2.7 million in Q4 2025 per SIGA's latest filing, from $3.3 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $6.5 million in Q4 2021 and bottomed at $2.7 million in Q4 2025.
- Historically, Other Non-Current Liabilities has averaged $4.0 million across 5 years, with a median of $3.5 million in 2022.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Liabilities tumbled 48.51% in 2022, then climbed 7.93% in 2024.
- Over 5 years, Other Non-Current Liabilities stood at $6.5 million in 2021, then sank by 48.51% to $3.4 million in 2022, then rose by 0.54% to $3.4 million in 2023, then slipped by 5.2% to $3.2 million in 2024, then retreated by 17.1% to $2.7 million in 2025.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $2.7 million, $3.3 million, and $3.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn |
| 10 | Siga Technologies | 235.60 Mn | 80.63 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 2.65 Mn |
| Sep 30, 2025 | 3.28 Mn |
| Jun 30, 2025 | 3.30 Mn |
| Mar 31, 2025 | 3.13 Mn |
| Dec 31, 2024 | 3.20 Mn |
| Sep 30, 2024 | 3.61 Mn |
| Jun 30, 2024 | 3.72 Mn |
| Mar 31, 2024 | 3.34 Mn |
| Dec 31, 2023 | 3.38 Mn |
| Sep 30, 2023 | 3.50 Mn |
| Jun 30, 2023 | 3.45 Mn |
| Mar 31, 2023 | 3.35 Mn |
| Dec 31, 2022 | 3.36 Mn |
| Sep 30, 2022 | 3.63 Mn |
| Jun 30, 2022 | 3.48 Mn |
| Mar 31, 2022 | 6.17 Mn |
| Dec 31, 2021 | 6.52 Mn |
| Sep 30, 2021 | 6.34 Mn |
| Jun 30, 2021 | 5.30 Mn |
| Mar 31, 2021 | 5.72 Mn |